|
Jul 1
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025
|
|
Jun 20
|
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
|
|
Jun 17
|
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025
|
|
Jun 2
|
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
|
|
Jun 2
|
Ipsen S.A. - Initiation of the share buy-back program
|
|
May 31
|
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
|
|
May 12
|
Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
|
|
May 7
|
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
|
|
Mar 12
|
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins
|
|
Feb 13
|
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
|